Alzamend Neuro, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.84M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company’s pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Details
| Name | Alzamend Neuro, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 6 |
| Founded | 2016 |
| Ipo Date | 2021-06-15 |
| Ceo | Stephan Jackman |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| Ipo Price | 5.00 |
| Isin | US02262M6057 |
| Cusip | 02262M605 |
| Cik | 1677077 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Stephan Jackman | Chief Executive Officer and Director |
| Milton Charles Ault III | Founder and Vice Chairman |
| David J. Katzoff | Chief Financial Officer |
| Henry C. W. Nisser Esq. | Executive Vice President, General Counsel and Director |
| Kenneth S. Cragun CPA | Senior Vice President of Finance |
Contact
| Address | 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, Georgia 30326, United States |
| Phone | 844 722 6333 |
| Website | https://www.alzamend.com |